Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

University Health Network

Headquarters: Toronto, ON, Canada
Year Founded: 1999
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Feb 7, 2025
Product Development

The radiopharma landscape takes shape in neuroendocrine tumors

Itm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map
BioCentury | Mar 26, 2024
Distillery Therapeutics

HFE2 for blood-brain barrier integrity in MS

BioCentury | Apr 29, 2022
Discovery & Translation

Neoantigen-reactive T cell signatures; plus CAR T cell therapy improvements and more

BioCentury’s roundup of translational news
BioCentury | Oct 27, 2021
Distillery Therapeutics

MIF identified as spondyloarthritis target

BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

Kronos raises $250M in NASDAQ IPOLook for shares of Kronos Bio Inc. (NASDAQ:KRON) to begin trading on Friday after the company raised $250 million in an IPO. The listing completes a busy few months
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Immune system biomarkers take center stage among emerging targets at ASH 2019
BioCentury | Apr 12, 2019
Emerging Company Profile

Bright Angel: New hope against fungal resistance

How Bright Angel's HSP90 inhibitor could block antifungal resistance
Items per page:
1 - 10 of 76